Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 20/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1135922 | 0.84 | CCR1 (0.56) | CCR1KCNH2 | |
| SCHEMBL1255967 | 0.83 | NOTUM (0.48) | CCR1 | |
| SCHEMBL1670263 | 0.80 | CCR1 (0.44) | CCR1 | |
| SCHEMBL1135708 | 0.80 | CCR1 (0.44) | CCR1 | |
| SCHEMBL1135433 | 0.80 | CCR1 (0.44) | CCR1KCNH2 | |
| SCHEMBL1872739 | 0.78 | PTGS2 (0.42) | CCR1CYP3A4 | |
| SCHEMBL1135920 | 0.78 | CCR1 (0.76) | CCR1KCNH2 | |
| SCHEMBL1135640 | 0.77 | MAPK14 (0.49) | CCR1 | |
| SCHEMBL1253896 | 0.76 | CCR1 (0.64) | CCR1KCNH2ADRB1CYP3A4 | |
| SCHEMBL1135201 | 0.76 | CCR1 (0.61) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056858-B2 | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| EP-2285783-B1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-05-21 | — | — | EP | disclosed |
| EP-2491028-B1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-12-11 | — | — | EP | disclosed |
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-8263597-B2 | Indazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| EP-2491028-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| WO-2011049917-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCRL2 | CCR1 1/4885KCNH2 3693/4885ADRB1 319/4885 |
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | CCR1, CCRL2, CCR3 | CCR1 1/4885KCNH2 979/4885ADRB1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.